Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production.

OBJECTIVE Trained immunity (TI) is a de facto memory program of innate immune cells, characterized by immunometabolic and epigenetic changes sustaining enhanced production of cytokines. TI evolved as a protective mechanism against infections; however, inappropriate activation can cause detrimental inflammation and might be implicated in the pathogenesis of chronic inflammatory diseases. In this study, we investigated the role of TI in the pathogenesis of giant cell arteritis (GCA), a large-vessel vasculitis characterized by aberrant macrophage activation and excess cytokine production. METHODS Monocytes from GCA patients and from age- and sex-matched healthy donors were subjected to polyfunctional studies, including cytokine production assays at baseline and following stimulation, intracellular metabolomics, chromatin immunoprecipitation-qPCR, and combined ATAC/RNA sequencing. Immunometabolic activation (i.e. glycolysis) was assessed in inflamed vessels of GCA patients with FDG-PET and immunohistochemistry (IHC), and the role of this pathway in sustaining cytokine production was confirmed with selective pharmacologic inhibition in GCA monocytes. RESULTS GCA monocytes exhibited hallmark molecular features of TI. Specifically, these included enhanced IL-6 production upon stimulation, typical immunometabolic changes (e.g. increased glycolysis and glutaminolysis) and epigenetic changes promoting enhanced transcription of genes governing pro-inflammatory activation. Immunometabolic changes of TI (i.e. glycolysis) were a feature of myelomonocytic cells in GCA lesions and were required for enhanced cytokine production. CONCLUSIONS Myelomonocytic cells in GCA activate TI programs sustaining enhanced inflammatory activation with excess cytokine production.

[1]  M. Hashimoto,et al.  Pathogenic role of monocytes/macrophages in large vessel vasculitis , 2022, Frontiers in Immunology.

[2]  E. Ballestar,et al.  Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids , 2022, Annals of the Rheumatic Diseases.

[3]  C. Doglioni,et al.  Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis. , 2021, Rheumatology.

[4]  P. Nienhuis,et al.  Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis , 2021, Rheumatology.

[5]  A. Tomelleri,et al.  Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage , 2021, The Lancet Rheumatology.

[6]  L. Joosten,et al.  Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. , 2021, Blood.

[7]  L. Joosten,et al.  The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. , 2021, Cell reports.

[8]  J. Stone,et al.  Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial , 2021 .

[9]  L. Joosten,et al.  Trained Immunity: Reprogramming Innate Immunity in Health and Disease. , 2021, Annual review of immunology.

[10]  L. Joosten,et al.  The Intersection of Epigenetics and Metabolism in Trained Immunity. , 2020, Immunity.

[11]  E. Matteson,et al.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica , 2020, Nature Reviews Rheumatology.

[12]  M. Oosting,et al.  BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment , 2020, Cell Host & Microbe.

[13]  T. Kishimoto,et al.  Translating IL-6 biology into effective treatments , 2020, Nature Reviews Rheumatology.

[14]  R. Xavier,et al.  Defining trained immunity and its role in health and disease , 2020, Nature Reviews Immunology.

[15]  L. Joosten,et al.  Therapeutic targeting of trained immunity , 2019, Nature Reviews Drug Discovery.

[16]  P. Giorgi Rossi,et al.  Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study , 2018, Rheumatology.

[17]  C. Doglioni,et al.  3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target , 2018, Annals of the rheumatic diseases.

[18]  A. Iagnocco,et al.  EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice , 2018, Annals of the rheumatic diseases.

[19]  E. Matteson,et al.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities , 2017, Nature Reviews Rheumatology.

[20]  J. Stone,et al.  Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.

[21]  A. Rizzo,et al.  New insights into the pathogenesis of giant cell arteritis. , 2017, Autoimmunity reviews.

[22]  L. Joosten,et al.  Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance , 2017, Proceedings of the National Academy of Sciences.

[23]  L. Joosten,et al.  Immunometabolic circuits in trained immunity. , 2016, Seminars in immunology.

[24]  J. Rathmell,et al.  A guide to immunometabolism for immunologists , 2016, Nature Reviews Immunology.

[25]  S. Reichenbach,et al.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[26]  R. Xavier,et al.  Trained immunity: A program of innate immune memory in health and disease , 2016, Science.

[27]  S. Raimondo,et al.  Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis , 2016, Annals of the rheumatic diseases.

[28]  W. Dixon,et al.  Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force , 2016, Annals of the rheumatic diseases.

[29]  E. Pearce,et al.  Immunometabolism governs dendritic cell and macrophage function , 2016, The Journal of experimental medicine.

[30]  Howard Y. Chang,et al.  ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.

[31]  R. Xavier,et al.  mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity , 2014, Science.

[32]  C. Weyand,et al.  Immune mechanisms in medium and large-vessel vasculitis , 2013, Nature Reviews Rheumatology.

[33]  C. Campochiaro,et al.  The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases , 2013, Annals of the rheumatic diseases.

[34]  R. Xavier,et al.  Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. , 2012, Cell host & microbe.

[35]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[36]  L. Mouthon,et al.  Pathogenesis of giant cell arteritis: More than just an inflammatory condition? , 2010, Autoimmunity reviews.

[37]  D. Colomer,et al.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.

[38]  G. Hunder,et al.  Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. , 1993, Arthritis and rheumatism.

[39]  J. Farmer,et al.  Giant Cell Arteritis and Polymyalgia Rheumatica , 1987, The Annals of otology, rhinology, and laryngology.